May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combination Therapy: Lucentis (Ranibizumab Injection) and Xibrom (Bromfenac Ophthalmic Solution) 0.09% in the Treatment of Choroidal Neovascular Membrane Secondary to Age-Related Macular Degeneration
Author Affiliations & Notes
  • C. A. Grant
    Vitreoretinal Surgery, Advanced Retinal Institute, Inc, Palos Heights, Illinois
  • Footnotes
    Commercial Relationships  C.A. Grant, Ista Pharm, C.
  • Footnotes
    Support  Unrestricted educational grant by Ista Pharm
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 563. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. A. Grant; Combination Therapy: Lucentis (Ranibizumab Injection) and Xibrom (Bromfenac Ophthalmic Solution) 0.09% in the Treatment of Choroidal Neovascular Membrane Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):563. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate adjuvant bromfenac in ranibizumab treatment of choroidal neovascularization secondary to Age-related Macular Degeneration for the possible modulation of the duration of treatment.

Methods: : In a retrospective case series, 60 patients on ranibizumab therapy for choroidal neovascular membrane were treated with and without combined bromfenac twice a day, with 30 in each group. The patients were evaluated with fluorescein angiography, ocular coherence tomography, and visual acuity assessment for every 4-5 weeksperiod of six months. Patients with activity leakage as demonstrated by OCT underwent subsequent injections of ranibizumab.

Results: : Patients treated with bromfenac received 1.6 ± 0.69 injections of ranibizumab during the study period compared to 4.5 ± 0.41 injections of ranibizumab in patients without bromfenac. Patients with ranibizumab alone received significantly more (2.83 times) injections of ranibizumab (p=0.0002). Visual acuity increased 0.93 ± 3.92 in bromfenac treated patients and 0.06 Patients treated with bromfenac received 1.6 ± 0.69 injections of ranibizumab during the study period compared to 4.5 ± 0.41 injections of ranibizumab in patients without bromfenac. Patients with ranibizumab alone received significantly more (2.83 times) injections of ranibizumab (p=0.0002). Visual acuity increased 0.93 ± 3.92 lines in bromfenac treated patients and 0.06 ± 0.49 (p=0.06) in patients without bromfenac. Optical coherence tomography and fluorescein angiography data followed similar trends. There were no adverse events associated with the extended topical administration of bromfenac. Optical coherence tomography and fluorescein angiography data followed similar trends. There were no adverse events associated with the extended topical administration of bromfenac.

Conclusions: : Bromfenac may have a role in significantly decreasing the number of injections of ranibizumab needed to control choroidal neovascular membrane associated with Age-Related Macular Degeneration. A prospective study is indicated to further delineate the interaction.

Keywords: choroid: neovascularization • macula/fovea • degenerations/dystrophies 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×